Cargando…

Systemic capillary leak syndrome (SCLS) after receiving BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccine

Systemic capillary leak syndrome (SCLS), also known as Clarkson’s disease, is a rare disorder of unknown aetiology. Since SCLS was first described in 1960, fewer than 500 cases have been reported. SCLS is diagnosed by the classic triad of hypotension, haemoconcentration and hypoalbuminaemia resultin...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Masatoshi, Yasue, Yu, Kobayashi, Yoichi, Sugiyama, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928276/
https://www.ncbi.nlm.nih.gov/pubmed/35292552
http://dx.doi.org/10.1136/bcr-2022-248927
_version_ 1784670607952052224
author Inoue, Masatoshi
Yasue, Yu
Kobayashi, Yoichi
Sugiyama, Yutaka
author_facet Inoue, Masatoshi
Yasue, Yu
Kobayashi, Yoichi
Sugiyama, Yutaka
author_sort Inoue, Masatoshi
collection PubMed
description Systemic capillary leak syndrome (SCLS), also known as Clarkson’s disease, is a rare disorder of unknown aetiology. Since SCLS was first described in 1960, fewer than 500 cases have been reported. SCLS is diagnosed by the classic triad of hypotension, haemoconcentration and hypoalbuminaemia resulting from fluid extravasation. Some reports show that SCLS may sometimes occur as a side effect of adenoviral vector COVID-19 vaccines, although there is only one report (two cases) of SCLS after receiving a messenger RNA vaccine. Survival rates for SCLS are very poor without treatment, so it is crucial for clinicians to recognise this disorder. A middle-aged woman who presented with generalised malaise and anasarca after receiving the BNT162b2 COVID-19 vaccine was diagnosed with SCLS. Treatment with methylprednisolone and intravenous immunoglobulin was commenced and her symptoms resolved. We expect that this case report will add to the existing literature on this rare disorder and the side effects of vaccinations.
format Online
Article
Text
id pubmed-8928276
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-89282762022-04-01 Systemic capillary leak syndrome (SCLS) after receiving BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccine Inoue, Masatoshi Yasue, Yu Kobayashi, Yoichi Sugiyama, Yutaka BMJ Case Rep Case Reports: Rare disease Systemic capillary leak syndrome (SCLS), also known as Clarkson’s disease, is a rare disorder of unknown aetiology. Since SCLS was first described in 1960, fewer than 500 cases have been reported. SCLS is diagnosed by the classic triad of hypotension, haemoconcentration and hypoalbuminaemia resulting from fluid extravasation. Some reports show that SCLS may sometimes occur as a side effect of adenoviral vector COVID-19 vaccines, although there is only one report (two cases) of SCLS after receiving a messenger RNA vaccine. Survival rates for SCLS are very poor without treatment, so it is crucial for clinicians to recognise this disorder. A middle-aged woman who presented with generalised malaise and anasarca after receiving the BNT162b2 COVID-19 vaccine was diagnosed with SCLS. Treatment with methylprednisolone and intravenous immunoglobulin was commenced and her symptoms resolved. We expect that this case report will add to the existing literature on this rare disorder and the side effects of vaccinations. BMJ Publishing Group 2022-03-15 /pmc/articles/PMC8928276/ /pubmed/35292552 http://dx.doi.org/10.1136/bcr-2022-248927 Text en © BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.
spellingShingle Case Reports: Rare disease
Inoue, Masatoshi
Yasue, Yu
Kobayashi, Yoichi
Sugiyama, Yutaka
Systemic capillary leak syndrome (SCLS) after receiving BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccine
title Systemic capillary leak syndrome (SCLS) after receiving BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccine
title_full Systemic capillary leak syndrome (SCLS) after receiving BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccine
title_fullStr Systemic capillary leak syndrome (SCLS) after receiving BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccine
title_full_unstemmed Systemic capillary leak syndrome (SCLS) after receiving BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccine
title_short Systemic capillary leak syndrome (SCLS) after receiving BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccine
title_sort systemic capillary leak syndrome (scls) after receiving bnt162b2 mrna covid-19 (pfizer-biontech) vaccine
topic Case Reports: Rare disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928276/
https://www.ncbi.nlm.nih.gov/pubmed/35292552
http://dx.doi.org/10.1136/bcr-2022-248927
work_keys_str_mv AT inouemasatoshi systemiccapillaryleaksyndromesclsafterreceivingbnt162b2mrnacovid19pfizerbiontechvaccine
AT yasueyu systemiccapillaryleaksyndromesclsafterreceivingbnt162b2mrnacovid19pfizerbiontechvaccine
AT kobayashiyoichi systemiccapillaryleaksyndromesclsafterreceivingbnt162b2mrnacovid19pfizerbiontechvaccine
AT sugiyamayutaka systemiccapillaryleaksyndromesclsafterreceivingbnt162b2mrnacovid19pfizerbiontechvaccine